Expert Practice
Expert Practice
Expert Practice

Expert Practice in Pancreatic Cancer

Multidisciplinary Efforts to Improve Outcome

Not a member of My prIME? Join now for instant access.

Meeting Overview

Apply now to engage with experts in the field of pancreatic cancer (PCA) by joining this highly interactive 1.5-day live meeting. Our multidisciplinary experts will provide a comprehensive update on PCA biology and diagnosis, updates on the multimodality management of localized PCA, and the current standards and promising treatment strategies for metastatic PCA. This exciting meeting will use the following strategies:

  • Didactic presentations
  • Case-based presentations and clinical management discussions
  • Quiz questions
  • Q & A sessions

To apply for a travel grant, click on the Apply Now button.

Date and Location

Friday and Saturday
25 – 26 October 2019

Rooms: Opal, Topaz, Quartz, Sapphire
Vienna House Andel’s Prague
Stroupeznickeho 21
Prague, Czech Republic



25 – 26 October 2019



Prague, Czech Republic



7.0 European CME Credits (ECMEC®s)

Friday, 25 October – Day 1

13:00 Lunch
14:00 Welcome, introduction, and demographics
Philip Agop Philip, MD, PhD, FRCP; Thomas Seufferlein, MD, PhD; and Eric Van Cutsem, MD, PhD
14:10 Quiz: Are you up-to-date with pancreatic cancer (PCA) management?
Philip Agop Philip, MD, PhD, FRCP

Session I: PCA Biology and Diagnosis
Moderator: Eric Van Cutsem, MD, PhD

14:20 PCA: New insights
Volker Ellenrieder, MD, PhD
14:45 Q&A
14:55 Challenges in diagnosis and staging of PCA
Maria Antonietta Bali, MD, PhD
15:35 Use of endoscopy for diagnosis and management of PCA
Paolo G. Arcidiacono, MD, PhD
16:00 Q&A
16:10 Tumor board I: Localized PCA
Philip Agop Philip, MD, PhD, FRCP
17:10 Meet the professors
18:00 Evening break
19:00 Dinner

Saturday, 26 October – Day 2

07:30 Breakfast
08:30 Introduction and objectives of day 2
Thomas Seufferlein, MD, PhD

Session II: Updates on the Multimodality Management of Localized PCA
Moderator: Thomas Seufferlein, MD, PhD

08:35 Optimizing the role of surgery in the multimodality treatment of PCA
Massimo Falconi, MD
08:55 Expanding (neo)adjuvant systemic treatment options for resectable PCA
Teresa Macarulla, MD, PhD
09:15 Multidisciplinary panel commentary: Can we reach a consensus?
09:30 Role of radiotherapy in localized PCA
Carmen Rubio, MD, PhD
09:45 Ablative therapies for inoperable locally advanced PCA
Praveen Peddu, MBBS, MRCS, FRCR
10:05 Q&A
10:20 Coffee break

Challenging Cases From the Audience
Moderator: Eric Van Cutsem, MD, PhD

10:45 Borderline resectable PCA
11:05 Metastatic PCA: The continuum of care

Session III: Current Standards and Promising Treatment Strategies for Metastatic PCA
Moderator: Philip Agop Philip, MD, PhD, FRCP

11:25 Molecular testing to guide treatment in PCA: Is it ready for prime time?
Volker Ellenrieder, MD, PhD
11:40 Q&A
11:50 Tumor board II: Metastatic PCA
Thomas Seufferlein, MD, PhD
12:50 Lunch
13:50 Targeting DNA damage repair defects
Teresa Macarulla, MD, PhD
14:10 Q&A
14:20 Targeting PCA metabolism
Philip Agop Philip, MD, PhD, FRCP
14:40 Q&A
14:50 Targeting tumor microenvironment
Eric Van Cutsem, MD, PhD
15:10 Q&A
15:20 Quiz questions revisited and faculty commentary
Philip Agop Philip, MD, PhD, FRCP
15:35 prIME Points™ and closing remarks
Thomas Seufferlein, MD, PhD
15:40 Adjourn


  • Philip Agop Philip, MD, PhD, FRCPWayne State University and Karmanos Cancer Institute
    Detroit, Michigan, United States
  • Thomas Seufferlein, MD, PhD University of Ulm
    Ulm, Germany
  • Eric Van Cutsem, MD, PhDUniversity Hospitals Leuven
    Leuven, Belgium
  • Faculty

  • Paolo G. Arcidiacono, MD, PhDVita Salute San Raffaele University
    Milan, Italy
  • Maria Antonietta Bali, MD, PhDJules Bordet Institute
    Free University of Brussels
    Brussels, Belgium
  • Volker Ellenrieder, MD, PhDUniversity Hospital Gӧttingen
    Gӧttingen, Germany
  • Massimo Falconi, MDUniversity Vita-Salute San Raffaele
    IRCCS San Raffaele Hospital
    Milan, Italy
  • Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Praveen Peddu, MBBS, MRCS, FRCRKing's College Hospital
    NHS Foundation Trust
    London, United Kingdom
  • Carmen Rubio, MD, PhDHospital Clara Campal
    Madrid, Spain

This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with PCA.

After successful completion of this educational activity, participants should be able to:

  • Explain the complex biology of PCA and the role of genomic profiling
  • Describe the state-of-the-art process for diagnosing and staging of PCA
  • Evaluate multimodality treatment strategies for resectable, borderline resectable, and locally advanced PCA, taking into account the latest data on (neo)adjuvant chemotherapy and local therapies
  • Select the most appropriate therapeutic sequencing for individual patients with metastatic PCA
  • Define novel treatment strategies evaluated in PCA, including therapies targeting DNA repair defects, cancer cell metabolism, and tumor microenvironment

This educational activity is supported by Celgene, Erytech, and Rafael Pharmaceuticals.

Continuing Education


Expert Practice in Pancreatic Cancer: Multidisciplinary Efforts to Improve Outcome  held in Prague, Czech Republic on 25 – 26 October 2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 7.75 continuing professional development credits (CPD).


This activity is provided by prIME, a Medscape Oncology Company.

Sunshine Act/EFPIA

prIME, a Medscape Oncology Company complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.